The idea that you can burn fat and build muscle simultaneously is not a fitness myth. Research supports it. The process is called body recomposition and it happens when the right hormonal signals are present at the right time. The problem is most people optimizing for this outcome focus on calorie math and training alone and never look at the signaling layer underneath.

Growth hormone is the signal that drives both outputs. It triggers lipolysis, which is the release of stored fat from fat cells into the bloodstream, and it drives IGF-1 production, which is the downstream hormone responsible for lean mass signaling. Both outputs from the same mechanism. Both controlled by the same variable.

Growth hormone does not burn fat directly. What it does is send a signal to your fat cells that unlocks stored fat and releases it into the bloodstream where it can be used as fuel. That process is called lipolysis. The fat does not disappear on its own. It has to be unlocked first, and the strength of the signal determines how many fat cells open at the same time.

Think of your fat cells as storage containers with a lock on each one. Growth hormone is the signal that opens those locks. The higher GH climbs in your blood at the top of a pulse, the stronger that signal is, and the more containers open simultaneously. A weak signal opens fewer. The number that measures how high GH climbs is called GH pulse height, and it is measured in serum, which is just the liquid portion of your blood.

The lean mass connection runs through the same mechanism. When GH rises, it signals the liver to produce IGF-1. IGF-1 stands for insulin-like growth factor 1 and it is the downstream hormone that tells the body to build and preserve muscle tissue. The liver produces IGF-1 in proportion to the GH signal it receives. Higher GH pulse height means more IGF-1 produced. More IGF-1 means a stronger signal for lean mass building and preservation. Fat mobilization from the pulse. Lean mass signaling from the IGF-1 response. Both from the same mechanism, both controlled by the same upstream variable.

Tesamorelin works by sending a signal to the pituitary gland to produce more of its own growth hormone. That signal follows a pulsatile pattern, meaning GH rises and falls the way the body intends it to. The clinical evidence behind tesamorelin is the strongest of any GH secretagogue available. It preserves pituitary function, your body's own feedback loop stays intact, and research supports meaningful visceral fat reduction at the doses researchers typically use. None of that is being challenged here.

What is being challenged is the assumption that 2mg of tesamorelin and 1 IU of exogenous HGH produce comparable fat burning output. Based on the data, they do not. The reason is the ceiling. The pituitary can only push a GH pulse so high, even under the best stimulation. Tesamorelin sends the signal, but the body responds within the range of its own biology.

There is also a braking signal called somatostatin. Somatostatin is the hormone that tells the pituitary to slow GH production whenever output climbs. This brake is always engaged to some degree. It is part of how the body protects its own equilibrium. The result is a GH pulse that is higher than untreated baseline but still capped by what the pituitary can produce with that brake engaged. For most researchers in their late 40s and early 50s where natural GH capacity has already declined, that ceiling sits well below the pulse height that 1 IU of exogenous HGH delivers directly into circulation.

Exogenous HGH removes that ceiling entirely. When you inject 1 IU, you are not asking the pituitary to produce anything. You are delivering GH directly into the bloodstream. The pulse height does not depend on how well the pituitary responds to a signal. It does not depend on how much somatostatin is present or sleep quality the night before. The pulse height is set directly. Research suggests that for most researchers in the 45 to 55 age range, 1 IU of exogenous HGH will produce a GH pulse height that 2mg of tesamorelin cannot match.

If exogenous HGH produces a higher pulse height and stronger fat mobilization output at 1 IU, the obvious question is why cover GH secretagogues at all. The answer is that GH pulse height is not the only variable that matters across a long research window.

Research suggests that extended exogenous HGH use can reduce the pituitary's own output capacity over time. The body stops receiving the natural signal to produce GH on its own and natural production can decline as a result. That suppression risk is meaningfully lower with tesamorelin because the stimulation comes from within the system rather than bypassing it. These are real tradeoffs that belong in the protocol decision, especially for researchers thinking about what their GH profile looks like after the protocol ends.

For a researcher running a defined protocol with the specific goal of losing fat and building lean mass at the same time, the GH pulse height advantage of exogenous HGH at a low 1 IU dose produces superior output on both measures. For a researcher building a long-term protocol with pituitary health as a priority, tesamorelin produces meaningful results within a safer suppression profile. The goal defines the tool.

This content is for educational and research purposes only. It is not medical advice and is not intended to guide human use of any compound. Always consult a qualified medical provider before making decisions about your health or protocol.